Robert W. Baird reissued their hold rating on shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) in a research note published on Friday. They currently have a $2.00 price target on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on PRTO. Zacks Investment Research cut shares of Proteon Therapeutics from a hold rating to a strong sell rating in a research report on Saturday. HC Wainwright reissued a hold rating and set a $2.30 target price on shares of Proteon Therapeutics in a research report on Wednesday. Cowen and Company reissued a hold rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. Finally, Oppenheimer Holdings, Inc. reissued a market perform rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. Proteon Therapeutics has a consensus rating of Hold and a consensus price target of $6.13.

Shares of Proteon Therapeutics (NASDAQ PRTO) traded up $0.05 on Friday, hitting $1.85. 32,600 shares of the stock traded hands, compared to its average volume of 47,141. Proteon Therapeutics has a 52-week low of $1.10 and a 52-week high of $11.45.

ILLEGAL ACTIVITY WARNING: “Proteon Therapeutics, Inc. (PRTO) Given Hold Rating at Robert W. Baird” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/12/proteon-therapeutics-inc-prto-given-hold-rating-at-robert-w-baird.html.

An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC purchased a new stake in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up 0.2% of RA Capital Management LLC’s investment portfolio, making the stock its 22nd biggest holding. RA Capital Management LLC owned about 7.59% of Proteon Therapeutics at the end of the most recent reporting period. 47.07% of the stock is currently owned by hedge funds and other institutional investors.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Stock Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related stocks with our FREE daily email newsletter.